Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events - REPLACE 2


The REPLACE 2 trial compared the use of bivalirudin during elective or urgent percutaneous coronary intervention (PCI) with: 1) unfractionated heparin with planned glycoprotein (GP) IIb/IIIa inhibitor use, and 2) unfractionated heparin alone, based on historical controls from the EPISTENT and ESPRIT trial.